FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice

Japanese Journal of Cancer Research

Volumn 89, Issue 12, 1998, Pages 1306-1317

  Naoe, Yoshinori ^a   Inami, Masamichi ^a   Matsumoto, Sanae ^a   Takagaki, Shoji ^b   Fujiwara, Tomoichi ^b   Yamazaki, Sachiko ^b   Kawamura, Ikuo ^a   Nishigaki, Fusako ^a   Tsujimoto, Susumu ^a   Manda, Toshitaka ^a   Shimomura, Kyoichi ^a  

^a Pharmacol Research Laboratories   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Antitumor effect; FK317; Human tumor xenograft; Mitomycin C; Selective toxicity

Indexed keywords

1 ACETYL 8 CARBAMOYLOXYMETHYL 3,9 EPOXY 5 FORMYL 1A,2,3,8,9,9A HEXAHYDRO 9 HYDROXY 7 METHOXY 1H AZIRINO[2,3 C][1]BENZAZOCINE ACETATE; ANTINEOPLASTIC AGENT; NEW DRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER INHIBITION; EXPERIMENTAL NEOPLASM; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; THIN LAYER CHROMATOGRAPHY; TUMOR XENOGRAFT;

EID: 0032448967     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1998.tb00528.x     Document Type: Article

References (28)

1. Iwami, M., Kiyoto, S., Terano, H., Kohsaka, M., Aoki, H. and Imanaka, H. A new antitumor antibiotic, FR-900482 (I). Taxonomic studies on the producing strain: a new species of genus Streptomyces. J. Antibiot. (Tokyo), 40, 589-593 (1987).
2. Kiyoto, S., Shibata, T., Yamashita, M., Komori, T., Okuhara, M., Terano, H., Kohsaka, M. and Aoki, H. A new antitumor antibiotic, FR-900482 (II). Production, isolation, characterization and biological activity. J. Antibiot. (Tokyo), 40, 594-599 (1987).
3. Shimomura, K., Hirai, O., Mizota, T., Matsumoto, S., Mori, J., Shibayama, F. and Kikuchi, H. A new antitumor antibiotic, FR-900482 (III). Antitumor activity in transplantable experimental tumors. J. Antibiot. (Tokyo), 40, 600-606 (1987).
4. Shimomura, K., Manda, T., Mukumoto, S., Masuda, K., Nakamura, T., Mizota, T., Matsumoto, S., Nishigaki, F., Oku, T., Mori, J. and Shibayama, F. Antitumor activity and hematotoxicity of a new, substituted dihydro-benzoxazine, FK973, in mice. Cancer Res., 48, 1166-1172 (1988).
5. Majima, H., Hasegawa, K., Fukuoka, M., Furuse, K., Wakui, A., Furue, H., Masaoka, T., Hattori, T., Taguchi, T., Ogura, T. and Niitani, H. Phase I clinical and pharmacokinetic study of FK973. Proc. Am. Soc. Clin. Oncol., 9, 78 (1990).
6. Pazdur, R., Ho, D. H., Daugherty, K., Bradner, W. T., Krakoff, I. H. and Raber, M. N. Phase I trial of FK973: description of a delayed vascular leak syndrome. Invest. New Drugs, 9, 337-382 (1991).
7. Naoe, Y., Inami, M., Matsumoto, S., Nishigaki, F., Tsujimoto, S., Kawamura, I., Miyayasu, K., Manda, T. and Shimomura, K. FK317; a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome. Cancer Chemother. Pharmacol., 42, 31-36 (1998).
8. Kennedy, K. A., Teicher, B. A., Rockwell, S. and Sartorelli, A. C. The hypoxic tumor cell: a target for selective cancer chemotherapy. Biochem. Pharmacol., 29, 1-8 (1980).
9. Teicher, B. A., Lazo, J. S. and Sartorelli, A. C. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res., 41, 73-81 (1981).
10. Naoe, Y., Inami, M., Kawamura, I., Nishigaki, F., Tsujimoto, S., Matsumoto, S., Manda, T. and Shimomura, K. Cytotoxic mechanisms of FK317, a new class of bioreductive agent with potent antitumor activity. Jpn. J. Cancer Res., 89, 666-672 (1998).
11. Pike, B. and Robinson, W. A. Human bone marrow colony growth in agar-gel. J. Cell Physiol., 76, 77-84 (1970).
12. Till, J. E. and McCulloch, A. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat. Res., 14, 213-222 (1961).
13. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods, 65, 55-63 (1983).
14. Fujita, M., Hayata, S. and Taniguchi, T. Relationship of chemotherapy on human cancer xenografts in nude mice to clinical response in donor patients. J. Surg. Oncol., 15, 211-219 (1980).
15. Fiebig, H. H., Schuchhardt, C., Henss, H., Fiedler, L. and Lohr, G. W. Comparison of tumor response in nude mice and in patients. Behring Inst. Mitt., 74, 343-352 (1984).
16. Winograd, B., Boven, E., Lobbezoo, M. W. and Pinedo, H. M. Human tumor xenografts in the nude mouse and their value as the test models in anticancer drug development. In Vivo (Athens), 1, 1-13 (1987).
17. Silver, R. T., Lauper, R. D. and Jarowski, C. I. In "A Synopsis of Cancer Chemotherapy" (1977). The York Medical Group, Dun-Donnelley Publishing Co., New York.
18. Carter, S. K., Bakowski, M. T. and Hellmann, K. In "Chemotherapy of Cancer" (1981). Wiley, New York.
19. Phillips, F. S., Schwartz, H. S. and Sternberg, S. S. Pharmacology of mitomycin C. I. Toxicity and pathologic effects. Cancer Res., 20, 1354-1361 (1960).
20. Schuring, J. E., Florczyk, A. P. and Bradner, W. T. The mouse as a model for predicting the myelosuppressive effects of anticancer drugs. Cancer Chemother. Pharmacol., 16, 243-246 (1986).
21. Bissery, M. C., Renard, A. and Andre, S. Preclinical pharmacology and toxicology of Taxotere (RP56976, NSC628503). Ann. Oncol., 3, 121 (1992).
22. Iyer, V. N. and Szybalski, W. A molecular mechanism of mitomycin C action: linking of complementary DNA strands. Proc. Natl. Acad. Sci. USA, 50, 355-362 (1963).
23. Iyer, V. N. and Szybalski, W. Mitomycins and porfiromycin: chemical mechanism of activation and cross linking of DNA. Science, 145, 55-58 (1964).
24. Keyes, S. R., Fracasso, P. M., Heimbrook, D. C., Rockwell, S., Sligar, S. G. and Sartorelli, A. C. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Res., 44, 5638-5643 (1984).
25. Schwartz, H. S. and Phillips, F. S. Pharmacology of mitomycin C. II. Renal excretion and metabolism by tissue homogenates. J. Pharmacol. Exp. Ther., 133, 335-342 (1961).
26. Schwartz, H. Pharmacology of mitomycin C. III. In vitro metabolism by rat liver. J. Pharmacol. Exp. Ther., 136, 250-258 (1962).
27. Crook, S. T. and Bradner, W. T. Mitomycin C: a review. Cancer Treat. Ther. Rev., 3, 121-139 (1976).
28. Naoe, Y., Inami, M., Takagaki, S., Matsumoto, S., Kawamura, I., Nishigaki, F., Tsujimoto, S., Manda, T. and Shimomura, K. Different effects of FK317 to multidrug-resistant tumor in vivo and in vitro. Jpn. J. Cancer Res., 89, 1047-1054 (1998).